Current filters:

Orexo AB

1 to 9 of 10 results

OX-MPI project returned to Orexo

OX-MPI project returned to Orexo


Swedish drug developer Orexo says that German family-owned pharma major Boehringer Ingelheim has decided…

Boehringer IngelheimGermanyLicensingOrexo ABPharmaceuticalProstaglandin ESweden

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests


Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

Orexo gets US FDA approval for opioid dependence drug Zubsolv


Swedish drug developer Orexo (STO: ORX) today (July 4) received approval from the US Food and Drug Administration…

Orexo ABPharmaceuticalReckitt BenckiserRegulationSuboxoneZubsolv

Sweden's Orexo in respiratory research accord with AstraZeneca


Swedish drug developer Orexo AB (STO: ORX) has entered into an agreement with Anglo-Swedish drug major…

AstraZenecaLicensingOrexo ABOX-CLIPharmaceuticalResearchRespiratory and Pulmonary

Orexo to explore strategic alternatives for commercialization in the USA


Swedish specialty pharmaceutical company Orexo (STO:ORX), with a focus on innovative sublingual drug…

AbstralLicensingMarkets & MarketingNeurologicalNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserSuboxoneZubsolv

Orexo and ProStrakan reconfigure rights to Abstral


Sweden's Orexo AB (STO: ORX) and Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa…

AbstralGlobalKyowa Hakko KirinLicensingOncologyOrexo ABPharmaceuticalProStrakan

Janssen drops deal with Orexo for OX-CLI/OX-ESI


US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

1 to 9 of 10 results

Back to top